VistaGen reports exploratory trial data show fasedienol eases anxiety in very severe social anxiety subgroup
VTGN•VistaGen reported exploratory findings suggesting fasedienol nasal spray improved anxiety versus placebo in a very severe social anxiety subgroup during a public speaking challenge, although the broader Phase 3 study missed its main goal.
1. Exploratory findings
VistaGen disclosed the findings at Psych Congress 2026. Analyses suggested repeat dosing may add benefit, while safety and tolerability remained consistent with prior trials and no serious drug-related safety signals were identified.
